Analyst consensus rating
CorMedix Analyst Rating: none
CRMD is rated none by 5 analysts with a $15.40 target. As of 2026-08-30.
Direct answer
CorMedix's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $15.40.
Forecast evidence checked August 30, 2026.
Get free CorMedix email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $8.30
- Average price target
- $15.40
- High price target
- $19.00
- Low price target
- $13.00
- Low target gap
- +56.6%
- Target upside
- +85.5%
- High target gap
- +128.9%
- Target range width
- 72.3%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for CorMedix?
CorMedix has a verified none consensus. The same dataset has an average price target of $15.40.
How far are CorMedix's low and high targets from the recorded price?
The low target implies +56.6%, while the high target implies +128.9%.
How many analysts are included in CorMedix's consensus?
The verified consensus includes 5 analysts.
How is CorMedix's target upside or downside calculated?
The average target of $15.40 is divided by the recorded price of $8.30, then one is subtracted to produce +85.5%. This does not guarantee a future return.
When was CorMedix's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.